Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML), including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires refining patient selection. To this end, we analyzed two recent AML studies profiling the gene expression and ex vivo drug r...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Brian S., Khan, Suleiman A., Mason, Mike J., Ammad-ud-din, Muhammad, Potdar, Swapnil, Malani, Disha, Kuusanmäki, Heikki, Druker, Brian J., Heckman, Caroline, Kallioniemi, Olli, Kurtz, Stephen E., Porkka, Kimmo, Tognon, Cristina E., Tyner, Jeffrey W., Aittokallio, Tero, Wennerberg, Krister, Guinney, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302655/
https://www.ncbi.nlm.nih.gov/pubmed/34302041
http://dx.doi.org/10.1038/s41698-021-00209-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302655/
https://www.ncbi.nlm.nih.gov/pubmed/34302041
http://dx.doi.org/10.1038/s41698-021-00209-9

Ejemplares similares